{"id":"hes-130-04","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased bleeding risk"},{"rate":null,"effect":"Acute kidney injury"},{"rate":null,"effect":"Hyperchloremic acidosis"},{"rate":null,"effect":"Coagulopathy"}]},"_chembl":{"chemblId":"CHEMBL2108701","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HES 130/04 (hydroxyethyl starch with a molecular weight of 130 kDa and degree of substitution of 0.4) functions as a plasma volume expander used in fluid resuscitation. It remains in the intravascular space longer than crystalloid solutions, providing sustained hemodynamic support. The molecule's structure allows it to maintain colloid osmotic pressure, helping to restore circulating blood volume in hypovolemic states.","oneSentence":"HES 130/04 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:38.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma"}]},"trialDetails":[{"nctId":"NCT01444508","phase":"PHASE4","title":"Effect of Colloid Versus Crystalloid on Coagulation","status":"UNKNOWN","sponsor":"K. C. Rasmussen","startDate":"2011-09","conditions":"Bloodloss","enrollment":40},{"nctId":"NCT00542516","phase":"PHASE4","title":"Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2006-09","conditions":"Hip Replacement Arthroplasty","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Voluven, HES 130/04, B 05 AA 07, Fresenius Kabi A/S."],"phase":"marketed","status":"active","brandName":"HES 130/04","genericName":"HES 130/04","companyName":"K. C. Rasmussen","companyId":"k-c-rasmussen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HES 130/04, also known as Hydroxyethyl Starch 130/0.4, was studied in a clinical trial for its effect on blood loss during hip replacement arthroplasty. The trial compared HES 130/04 to Ringer's lactate for volemic expansion in this surgical context.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}